1. Home
  2. RELI vs SCNI Comparison

RELI vs SCNI Comparison

Compare RELI & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reliance Global Group Inc.

RELI

Reliance Global Group Inc.

HOLD

Current Price

$0.63

Market Cap

6.5M

Sector

Finance

ML Signal

HOLD

SCNI

Scinai Immunotherapeutics Ltd.

HOLD

Current Price

$0.94

Market Cap

4.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELI
SCNI
Founded
2013
2003
Country
United States
Israel
Employees
64
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
4.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RELI
SCNI
Price
$0.63
$0.94
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1M
41.7K
Earning Date
11-06-2025
11-24-2025
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$13,115,995.00
$1,147,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.55
Revenue Growth
N/A
303.87
52 Week Low
$0.61
$0.86
52 Week High
$5.11
$6.18

Technical Indicators

Market Signals
Indicator
RELI
SCNI
Relative Strength Index (RSI) 36.84 38.13
Support Level $0.68 $1.14
Resistance Level $0.83 $1.26
Average True Range (ATR) 0.06 0.10
MACD 0.00 0.02
Stochastic Oscillator 2.57 13.13

Price Performance

Historical Comparison
RELI
SCNI

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: